Date: 2012-12-20
Type of information: R&D agreement
Compound: novel antibiotics combining compounds from AstraZeneca’s preclinical beta lactamase inhibitor (BLI) and LegoChem’s preclinical cephalosporin antibiotic programs
Company: AstraZeneca (UK) LegoChem Biosciences (South Korea)
Therapeutic area: Infectious diseases
Type agreement: R&D
development
licensing
Action mechanism:
Disease: drug-resistant bacterial infections
Details: AstraZeneca has entered into a research and development option & license agreement with LegoChem Biosciences to develop a novel antibiotic to treat drug-resistant bacterial infections. The treatment will potentially combine compounds from AstraZeneca’s preclinical beta lactamase inhibitor (BLI) and LegoChem’s preclinical cephalosporin antibiotic programs to help break down bacteria’s resistance to cephalosporins. Under the terms of the agreement, each company will develop its single agent program through Phase I under the guidance of a joint research committee, and AstraZeneca will develop investigational combinations of compounds through Phase I during the option phase. AstraZeneca will be solely responsible for the development and commercialization of the candidate combination compound through the option phase, and thereafter if the option is exercised by AstraZeneca.
Financial terms: Under the terms of the collaboration, LegoChem is eligible to receive $2.45M in initial and preclinical milestones; $20M in development milestones and $116.5M in launch and commercial milestones, as well as tiered royalties.
Latest news:
